Axonics (NASDAQ:AXNX) quickly edged higher by 0.8% after a Nasdaq delisting notice for its planned sale to Boston Scientific ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Shares of Boston Scientific Corp. rose 1.1% in premarket trades Wednesday after the medical products company reported better-than-expected profit and sales in its third-quarter results ...

As Boston Scientific’s pulsed field ablation business continues to grow, the medtech aims to nourish the program with the ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

On an adjusted basis, Boston Scientific reported earnings of 63 cents a share, above the FactSet consensus of 59 cents a share. Sales were $4.209 billion, up 19.4% from $3.527 billion in the prior ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Strong sales of a medical device to treat atrial fibrillation helped lift Boston Scientific’s top line last quarter, but an unexpected pause in an important clinical trial to expand the use of ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

That said, let's delve into the average estimates of some Boston Scientific metrics that Wall Street analysts commonly model and monitor. It is projected by analysts that the 'Net Sales ...

Boston Scientific Corp. resumed enrollment in the AVANT GUARD trial of the Farapulse pulse field ablation (PFA) system after a pause reported in October “to assess a few unanticipated observations.” ...

Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.